Aprepitant
Therapeutic Indications
Aprepitant is indicated for:
Prevention of nausea and vomiting associated with chemotherapy
Irrespective of gender only Adults (18 years old or older)
Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 80-125 mg once daily
Prevention of nausea and vomiting associated with chemotherapy
Irrespective of gender only Adolescents (12 years - 18 years old)
Prevention nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adolescents from the age of 12.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 80-125 mg once daily
Contraindications
Active ingredient Aprepitant is contraindicated in the following cases:
Pimozide, terfenadine, astemizole, cisapride
No gender/age discrimination
Co-administration with pimozide, terfenadine, astemizole or cisapride is contraindicated.